Thorsten Gutjahr is a distinguished scientist and executive leader in Precision Medicine, Biomarkers and Companion Diagnostics. He currently holds the position of VP, Global Head of Precision Medicine Oncology within AstraZeneca’s Precision Medicine and Biosamples function. He leads the Global CDx team that since 2014 delivered more than 45 new CDx across US, EU, Japan and China, which include regulated diagnostics for olaparib, osimertinib, durvalumab and gefitinib. Thorsten plays a leadership role to develop AZ’s Precision Medicine strategy with a passion to develop novel clinical precision medicine strategies and to deploy artificial intelligence-based data approaches to define and identify those patients who benefit most from novel therapies. His experience in Oncology research combined with his profound background in Pharma Development as well as the Diagnostics business lays the foundation of his ambition is to realise ways to cure cancer with early and continued diagnostic testing going hand-in-hand with optimal treatment. Thorsten studied at the Universities of Stuttgart-Hohenheim and Tuebingen (Germany) as well as at the University of Sussex (UK). He gained his PhD in molecular biology at the University of Stuttgart (Germany), and was a research scientist at the Haematology/Oncology School of Medicine, University of California, San Diego.